Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Lin Zhang, Wuqian Mai, Wenyang Jiang, Qing Geng, Lin Zhang, Wuqian Mai, Wenyang Jiang, Qing Geng

Abstract

Sintilimab (Tyvyt®) is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approved to treat relapsed or refractory classical Hodgkin lymphoma in patients who have undergone two or more lines of systemic chemotherapy by the National Medical Products Administration of China. Recently, sintilimab has been reported in plenty of literature and shows satisfying anti-tumor effect. Meanwhile, there are some reports showing its side effects. Overall, sintilimab has similar anti-tumor effects and a better safety profile compared to nivolumab and pembrolizumab in Hodgkin lymphoma, natural killer/T cell lymphoma and advanced non-small cell lung cancer. In this review, we aim to briefly describe the mechanisms, pharmacological characteristics, anti-tumor effects, predictive parameters of efficacy and side effects of sintilimab, providing valuable information of sintilimab for decision-making in the treatment of tumors in the future.

Keywords: Hodgkin lymphoma; immunotherapy; non-small cell lung cancer; programmed cell death protein 1(/programmed cell-death protein 1 ligand 1; sintilimab; solid tumors.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhang, Mai, Jiang and Geng.

Figures

Figure 1
Figure 1
Timeline of sintilimab-related studies. Dates indicate the time when the study was first available online. CS, clinical study; ST, solid tumors; r/r cHL, relapsed or refractory classical Hodgkin lymphoma; ENKTL, extranodal NK/T cell lymphoma; CR, case report; GC, gastric cancer; ESCC, esophageal squamous cell carcinoma; AE, case reports on adverse effects; ICC, intrahepatic cholangiocarcinoma; CRC, colorectal cancer; HCC, hepatocellular carcinoma; SCLC, small cell lung cancer; RCC, renal cell carcinoma; DLBCL, diffuse large B-cell lymphoma; G/GEJ, gastric/gastroesophageal junction adenocarcinoma; NSCLC, non-small cell lung cancer.

References

    1. Edner NM, Carlesso G, Rush JS, Walker LSK. Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discovery (2020). 10.1038/s41573-020-0081-9
    1. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol (2018) 11:39. 10.1186/s13045-018-0582-8
    1. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res (2020) 30:660–9. 10.1038/s41422-020-0343-4
    1. Hoy SM. Sintilimab: First Global Approval. Drugs (2019) 79:341–6. 10.1007/s40265-019-1066-z
    1. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine (2020) 54:102731. 10.1016/j.ebiom.2020.102731
    1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 11:3887–95. 10.1002/j.1460-2075.1992.tb05481.x
    1. Kong X. Discovery of New Immune Checkpoints: Family Grows Up. Adv Exp Med Biol (2020) 1248:61–82. 10.1007/978-981-15-3266-5_4
    1. Wang J, Yang T, Xu J. Therapeutic Development of Immune Checkpoint Inhibitors. Adv Exp Med Biol (2020) 1248:619–49. 10.1007/978-981-15-3266-5_23
    1. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA (2001) 98:13866–71. 10.1073/pnas.231486598
    1. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 173:945–54. 10.4049/jimmunol.173.2.945
    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359:1350–5. 10.1126/science.aar4060
    1. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Brit J Cancer (2015) 112:1421–7. 10.1038/bjc.2015.124
    1. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 236:219–42. 10.1146/annurev.immunol.26.021607.090331
    1. Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv (2020) 6:eabd2712. 10.1126/sciadv.abd2712
    1. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 125:3384–91. 10.1172/JCI80011
    1. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 8:324r–8r. 10.1126/scitranslmed.aad7118
    1. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 111:3635–43. 10.1182/blood-2007-11-123141
    1. Wu Y, Gu W, Li J, Chen C, Xu ZP. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes. Nanomedicine(Lond) (2019) 14:955–67. 10.2217/nnm-2018-0237
    1. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell (2015) 162:1242–56. 10.1016/j.cell.2015.08.052
    1. Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs (2019) 11:1443–51. 10.1080/19420862.2019.1654303
    1. Zhang S, Zhang M, Wu W, Yuan Z, Tsun A, Wu M, et al. Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antib Ther (2018) 1:65–73. 10.1093/abt/tby005
    1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677–704. 10.1146/annurev.immunol.26.021607.090331
    1. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science (2007) 317:1554–7. 10.1126/science.1144603
    1. Chuanfei Y, Xingjun C, Wenbo W, Haiqing N, GUO AY, Lan W. [LC-MS analysis of sintilimab as an anti-PD-1 therapeutic mab for its improved hinge stability study](in Chinese). Acta Pharmaceu Sin (2019) 54:122–9. 10.16438/j.0513-4870.2018-0574
    1. Xu J, Jia R, Wang Y, Liu R, Zhao C, Zhou H, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. J Clin Oncol (2018) 36:e15125. 10.1200/JCO.2018.36.15_suppl.e15125
    1. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol (2019) 6:e12–9. 10.1016/S2352-3026(18)30192-3
    1. Instructions for sintilimab injection (2020). Available at: (Accessed October 4th).
    1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 25:579–86. 10.1200/JCO.2006.09.2403
    1. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol (2016) 17:1283–94. 10.1016/S1470-2045(16)30167-X
    1. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol (2017) 35:2125–32. 10.1200/JCO.2016.72.1316
    1. Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, et al. Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4). J Clin Oncol (2019) 37S:102–3. 10.1002/hon.66_2629
    1. Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol (2018) 11:15. 10.1186/s13045-018-0559-7
    1. Kwong YL, Chan T, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood (2017) 129:2437–42. 10.1182/blood-2016-12-756841
    1. Shi Y, Li Q, Zhang W, Nan Y, Yang T, Liang X, et al. Sintilimab as salvage treatment in an HIV patient with relapsed/ refractory Hodgkin: a case report. Ann Palliat Med (2020) 9:2414–9. 10.21037/apm-20-1333
    1. Zheng R, Chen X, Wang C, Qin P, Tan H, Luo X. Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion. Case Rep Hematol (2020) 2020:1–6. 10.1155/2020/8879448
    1. Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol (2020) 15:816–26. 10.1016/j.jtho.2020.01.017
    1. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, et al. Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. J Thorac Oncol (2012) 7:825–32. 10.1097/JTO.0b013e318247504a
    1. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KMW, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol (2014) 15:e42–50. 10.1016/S1470-2045(13)70334-6
    1. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med (2018) 378:1976–86. 10.1007/s00259-020-04711-3
    1. Bar J, Urban D, Ofek E, Ackerstein A, Redinsky I, Golan N, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223. J Clin Oncol (2019) 37:8534. 10.1200/JCO.2019.37.15_suppl.8534
    1. Ben Nun A, Golan N, Ofek E, Urban D, Kamer I, Simansky D, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Initial report of a phase I study, MK3475-223. Ann Oncol (2018) 29 Suppl 8:i486. 10.1093/annonc/mdy290.011
    1. Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S. Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer. J Thorac Oncol (2018) 13S:S1047. 10.1016/j.jtho.2018.10.018
    1. Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11). J Thorac Oncol (2020) 15:1636–46. 10.1016/j.jtho.2020.07.014
    1. Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol (2020) 38:1505–17. 10.1200/JCO.19.03136
    1. Zhang Y, Zhao M, Cao S, Zhang X, Du Y. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR -mutated non-small cell lung cancer patient: A case report. Thorac Cancer (2020) 11:2717–22. 10.1111/1759-7714.13569
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45:228–47. 10.1016/j.ejca.2008.10.026
    1. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol (2017) 18:e143–52. 10.1016/S1470-2045(17)30074-8
    1. Zhang L, Mai W, Hao B, Jiang W, Geng Q. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer. Med (Baltimore) (2020) 99:e19790. 10.1097/MD.0000000000019790
    1. Chen L, Han X, Gao Y, Zhao Q, Wang Y, Jiang Y, et al. Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review. Onco Targets Ther (2020) 13:4359–64. 10.2147/OTT.S248226
    1. Shan Q, Wang H, Han X, Guo J, Wang Z. Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. Thorac Cancer (2020) 11:3001–6. 10.1111/1759-7714.13600
    1. China National Medical Products Administration has accepted the application for a new indication of Tyvyt® (Sintilimab injection) to be used as a first-line therapy in combination with gemcitabine for the treatment of squamous non-small cell lung cancer. Available at: (Accessed August 13, 2020). (in Chinese).
    1. Inquiry of Drug Registration Progress. Available at: (Accessed August 13, 2020). (in Chinese).
    1. Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, et al. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer (2020) 20:760. 10.1186/s12885-020-07251-z
    1. Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol (2019) 30:250–8. 10.1093/annonc/mdy540
    1. Xu J, Li Y, Fan Q, Shu Y, Wu Z, Cui T, et al. Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2). J Clin Oncol (2020) 38:4511. 10.1200/JCO.2020.38.15_suppl.4511
    1. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. JAMA Oncol (2019) 5:546. 10.1001/jamaoncol.2018.5441
    1. Kato K, Cho BC, Takahashi M, Okada M, Lin C, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol (2019) 20:1506–17. 10.1016/S1470-2045(19)30626-6
    1. Zhang W, Bi X, Sun Y, Yu Y, Zhou J, Zeng H, et al. Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phase Ib study. J Clin Oncol (2020) 38:3079. 10.1200/JCO.2020.38.15_suppl.3079
    1. Gou M, Yan H, Liu Tie E, Wang Z, Si H, Chen S, et al. Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China. J Clin Oncol (2020) 38:4028. 10.1200/JCO.2020.38.15_suppl.4028
    1. Duan X, Zhang H, Zhou L, Jiang B, Mao X. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis. Digest Liver Dis (2020) 52:794–6. 10.1016/j.dld.2020.04.005
    1. Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy (2020) 12:555–61. 10.2217/imt-2019-0100
    1. Liu J, Wang C, Cao L, Li S. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. Ann Palliat Med (2020) 9:497–503. 10.21037/apm.2020.03.14
    1. Yi G. [Treatment of Advanced Digestive Tract Tumor with PD-1 Inhibitor in 2 Cases and Literature Review](in Chinese). Shandong Univ (2019) 45. 10.27272/d.cnki.gshdu.2019.000927
    1. Jin L. [Efficacay and safety of anti-PD-1 monoclonal antibody in the treatment of advanced malignant solid tumors](in Chinese). Zhejiang Univ (2019) 71. 10.27461/d.cnki.gzjdx.2019.001722
    1. Du Y, Si L, Mao L, Chi Z, Cui C, Guo J. [Efficacy of axitinib plus sintilimab in intermediate-and high-risk advanced renal cell carcinoma](in Chinese). Chin J Clin Oncol (2020) 47:513–6. 10.3969/j.issn.1000-8179.2020.10.342
    1. Clinical trials on sintilimab. Available at: (Accessed October 4th, 2020).
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med (1978) (2009) 50:122S–50S. 10.2967/jnumed.108.057307
    1. Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imag (2020) 47:1209–19. 10.1007/s00259-020-04711-3
    1. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf (1999) 20:109–17. 10.2165/00002018-199920020-00002
    1. Common Terminology Criteria for Adverse Events (CTCAE). Available at: (Accessed August 10th, 2020).
    1. Xu C, Chen Y, Du X, Liu J, Huang C, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ (2018) k4226. 10.1136/bmj.k4226
    1. Li J, Tao R, Fan L, Song Y, Hu Y, Zhang W, et al. Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4). J Clin Oncol (2020) 38:8050. 10.1200/JCO.2020.38.15_suppl.8050
    1. Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol (2019) 20:1395–408. 10.1016/S1470-2045(19)30407-3
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 372:2018–28. 10.1056/NEJMoa1501824
    1. Mok TSK, Wu Y, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (2019) 393:1819–30. 10.1016/S0140-6736(18)32409-7
    1. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387:1540–50. 10.1016/S0140-6736(15)01281-7
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New Engl J Med (2016) 375:1823–33. 10.1056/NEJMoa1606774
    1. Xing Q, Zhang Z, Lin Q, Shen L, Wang P, Zhang S, et al. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. Ann Transl Med (2020) 8:250. 10.21037/atm.2020.01.79
    1. Wen L, Zou X, Chen Y, Bai X, Liang T. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. Front Immunol (2020) 11:2076. 10.3389/fimmu.2020.02076
    1. Gao C, Xu J, Han C, Wang L, Zhou W, Yu Q. An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report. Ann Palliat Med (2020) 9:2393–9. 10.21037/apm-20-1310
    1. Ni J, Zhang L, Zhang X. Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. Eur J Cancer (2020) 128:57–9. 10.1016/j.ejca.2019.12.030
    1. Kang K, Zheng K, Zhang Y. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy. J Immunother (1997) (2020) 43:165–8. 10.1097/CJI.0000000000000314
    1. Hu J, Li Y, Chen X, Luo C, Zuo X. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. J Clin Pharm Ther (2020). 10.1111/jcpt.13217
    1. Chao-jun X, Ke-fu Y, Hui-xin J, Yu-han DU, Wei-xi C, Yue Z, et al. [Mini health technology assessment of five programmed cell death protein 1 inhibitors](in Chinese). Chin J Hosp Pharm (2020) 40:1638–42,1662. 10.13286/j.1001-5213.2020.15.08

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi